Norditropin (somatropin)
An approved treatment for Noonan Syndrome, Turner Syndrome and Prader-Willi Syndrome.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Somatropin wherever you encounter it, plus the key facts at a glance.
- Generic name
- Somatropin
- Brand name
- Norditropin
- Drug class
- Recombinant human growth hormone
- Manufacturer
- Novo Nordisk
- How it's taken
- Injection under the skin with a prefilled pen, 6 or 7 days a week
Norditropin is a growth hormone shot given under the skin with a prefilled FlexPro pen, 6 or 7 days a week[1].
- Its label covers children with short stature from Noonan syndrome or Turner syndrome and children with growth failure from Prader-Willi syndrome, along with growth hormone deficiency in children and adults, children born small for gestational age who have not caught up by age 2 to 4, and idiopathic short stature[1].
- The FDA added Noonan syndrome on May 31, 2007, Turner syndrome on September 20, 2007 and Prader-Willi syndrome on February 23, 2018[3][4][5].
- The label has no boxed warning, and Norditropin is not used in children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing problems, because sudden deaths have been reported[1].
We'll email you when Norditropin's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Somatropin fits
Norditropin (somatropin) is a daily growth hormone shot whose label covers short stature in children with Noonan syndrome or Turner syndrome and growth failure in children with Prader-Willi syndrome[1].
- The Norditropin label's uses in these syndromes are for height only, so the other features of each syndrome are cared for separately[1].
- For Noonan syndrome, Sogroya (somapacitan-beco), a longer-acting growth hormone given once a week, also has a label for growth failure in children 2.5 years and older[7].
- For Turner syndrome, the Genotropin, Humatrope, Omnitrope and Zomacton somatropin labels also list Turner syndrome[8][9][10][12].
- For Prader-Willi syndrome, the Genotropin and Omnitrope labels also list growth failure, and Vykat XR (diazoxide choline) is approved separately for hyperphagia, the constant hunger of the syndrome, in people 4 and older rather than for growth[8][10][11].
- The Norditropin label reports no trial comparing Norditropin directly with another growth hormone product, and it says side effect rates from one somatropin product's trials cannot always be compared with another's[1].
- Anyone weighing Norditropin can ask the child's endocrinologist how the daily pen, the dose checks and, in Prader-Willi syndrome, the sleep and airway checks before starting would fit the family's routine.
How Somatropin works
Somatropin is human growth hormone made with recombinant DNA technology in E. coli bacteria, and its 191 amino acids match the growth hormone made by the pituitary gland[1]. Somatropin attaches to growth hormone receptors on cells, which switches on proteins including IGF-1, a hormone that carries much of growth hormone's effect[1]. In children, the label says somatropin speeds growth by acting on the growth plates (epiphyses) at the ends of the long bones, which is why it is stopped for growth once those plates have closed[1].
Somatropin also changes metabolism: it increases protein building and fat breakdown, raises sugar output from the liver and can lower insulin sensitivity[1]. The label's uses in these 3 syndromes are about height, meaning short stature in Noonan syndrome and Turner syndrome and growth failure in Prader-Willi syndrome[1].
Side effects and safety
- Sudden death in Prader-Willi syndrome. reports of sudden death after starting somatropin in children with Prader-Willi syndrome who had severe obesity, a history of upper airway obstruction or sleep apnea, or an unidentified breathing infection; boys with these risk factors may be at greater risk than girls; children are checked for airway blockage and sleep apnea before starting, and treatment is paused for new or louder snoring or new sleep apnea
- Acute critical illness. not used during acute critical illness after open heart or abdominal surgery or multiple accidental injuries, or with acute respiratory failure; in 2 placebo-controlled trials in adults in intensive care who did not have growth hormone deficiency, 42% died on somatropin against 19% on placebo
- Tumors. not used with an active cancer; childhood cancer survivors treated with radiation to the head who later took somatropin had a higher risk of a second tumor, most often a meningioma; the label asks doctors to weigh the risks in children with rare genetic causes of short stature that raise cancer risk, and to watch moles (nevi) for growth or change
- High blood sugar and diabetes. can lower insulin sensitivity, especially at higher doses, and new type 2 diabetes has been reported; blood sugar is checked periodically, and the label names obesity, Turner syndrome and a family history of diabetes as risk factors
- Raised pressure around the brain (intracranial hypertension). headache, vision changes, nausea or vomiting with swelling of the optic nerve, usually in the first 8 weeks; an eye exam is done before starting and periodically, and the label says people with Turner syndrome may be at higher risk
- Serious allergic reactions. anaphylaxis and angioedema, a deep swelling of the skin, have been reported since approval
- Fluid retention. swelling, joint and muscle pain and carpal tunnel symptoms, mainly in adults, usually temporary and dose related
- Low cortisol (hypoadrenalism). can unmask low adrenal function in people at risk of pituitary hormone loss, and people already on steroid replacement may need a higher dose
- Underactive thyroid. may appear or worsen; thyroid tests are done periodically, and the label notes people with Turner syndrome have a built-in higher risk of autoimmune thyroid disease
- Slipped capital femoral epiphysis. the ball at the top of the thigh bone can slip at the growth plate, more often with endocrine disorders including Turner syndrome and during fast growth; a new limp or hip or knee pain is checked; the label lists this warning as changed in July 2025
- Worsening scoliosis. an existing sideways curve of the spine can progress during fast growth; somatropin has not been shown to cause new scoliosis
- Pancreatitis. reported in children and adults, possibly more often in children, and the label cites published reports that girls with Turner syndrome may be at greater risk; lasting severe belly pain is checked
- Fat loss at the injection site (lipoatrophy). can happen when shots go in the same spot over a long time; injection sites are rotated
- An eye exam (fundoscopy) before starting and periodically, to look for swelling of the optic nerve
- Blood sugar, periodically, and more closely with diabetes or its risk factors
- Thyroid function, periodically
- For Prader-Willi syndrome, a check for upper airway blockage and sleep apnea before starting, then watching weight, snoring and breathing infections
- Growth response, with a look for missed doses, low thyroid, poor nutrition, advanced bone age or antibodies to growth hormone if growth does not speed up, especially in the first year
- Existing scoliosis, for progression
- Cortisol, in people who have or are at risk of low adrenal function
- IGF-1 levels, used in adults to guide the dose
The current Norditropin label has no boxed warning[1]. Its warnings cover sudden death in children with Prader-Willi syndrome who are severely obese or have airway or breathing problems; higher death rates in critically ill adults; tumor growth or a second tumor; high blood sugar and diabetes; raised pressure around the brain; serious allergic reactions; fluid retention; low cortisol; an underactive thyroid; slipped capital femoral epiphysis, a hip problem at the growth plate; worsening of existing scoliosis; pancreatitis; and fat loss where shots are repeated[1].
The label lists upper respiratory infection, fever, sore throat, headache, ear infection, swelling, joint pain, tingling, muscle pain, flu-like illness and impaired glucose tolerance as common side effects across children and adults[1]. In the Noonan syndrome study, the most frequent side effects were upper respiratory infection, stomach flu, ear infection and influenza, heart-related problems were the second most reported group, and scoliosis was reported in 1 child on the lower dose and 4 on the higher dose[1].
In the Turner syndrome studies, the most frequent were flu-like illness, middle and outer ear infections, upper respiratory infection, stomach flu, eczema and raised fasting blood sugar; 3 girls on high doses had excess growth of the hands or feet, and 2 girls on 0.045mg/kg a day had serious worsening of existing scoliosis[1]. In 2 Prader-Willi syndrome studies of another somatropin product, reported side effects were swelling, aggressiveness, joint pain, raised pressure around the brain, hair loss, headache and muscle pain[1].
In adults with growth hormone deficiency, a 6-month placebo-controlled trial found swelling of the legs and arms in 42% on Norditropin against 8% on placebo, joint pain in 19% against 15% and muscle pain in 15% against 8%[1]. Blood levels of phosphorus, alkaline phosphatase, parathyroid hormone and IGF-1 may rise during treatment[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Somatropin
Norditropin is injected under the skin of the back of the upper arm, the abdomen, the buttock or the thigh, rotating sites each time[1]. For children, the doctor works out a weekly dose by body weight and splits it into equal shots given 6 or 7 days a week[1]. The label doses are up to 0.46mg/kg a week (up to 0.066mg/kg a day) for Noonan syndrome, up to 0.47mg/kg a week (up to 0.067mg/kg a day) for Turner syndrome and 0.24mg/kg a week (0.034mg/kg a day) for Prader-Willi syndrome, adjusted to how each child grows[1].
Treatment for growth stops once the growth plates have closed[1]. Norditropin comes as a clear, colorless liquid in single-patient FlexPro prefilled pens of 5mg/1.5mL (orange), 10mg/1.5mL (blue), 15mg/1.5mL (green) and 30mg/3mL (purple)[1]. The 5mg, 10mg and 15mg pens work with the FlexPro PenMate, an accessory device dispensed separately, and the 30mg pen does not[1].
A pen is never shared, even with a new needle[1]. Unused pens are kept in the refrigerator and never frozen; after the first shot, a pen lasts 4 weeks in the refrigerator or 3 weeks at room temperature up to 77°F[1]. The label says people on steroid replacement may need a higher steroid dose, people on oral estrogen may need more Norditropin, and diabetes medicines may need adjusting[1].
Availability and cost
Only available as the brand-name product.
A biologic made in bacteria and given every day for years. The label gives no price. Drugs@FDA lists Norditropin under its own biologics license, and no generic Norditropin is listed[2]. Several other somatropin brands are sold under their own labels, and each brand's approved uses differ[8][9][10][12]. NovoCare offers a savings offer for commercially insured patients, capped at $1,500 a year, and free drug for some people who qualify[14][15].
Help paying for Norditropin
With private insurance, the drugmaker's copay card can lower what you pay for Norditropin. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Norditropin Savings Offer: patients with commercial insurance may pay as little as $0 per year, with an annual maximum cap of $1,500. Not available to anyone with a government-funded prescription benefit; people with both commercial and government plans count as government-insured. FEHB, Health Exchange and state employee plans are not treated as government programs. Enrollment is online at NorditropinSavings.com.
For: private insurance · source - Free medicine program
NovoCare Patient Assistance Program: may give Norditropin free to patients who lack insurance coverage and have limited financial means, until insurance or financial circumstances change. Eligibility is reviewed quarterly and renewed annually. The health care provider completes the Patient Enrollment Form. No income limit is published.
For: no insurance · source - Insurance and case manager help
NovoCare case managers help with coverage and assistance at 1-888-668-6444, 8:00 AM to 8:00 PM ET, Monday to Friday, and contact the prescriber within 48 business hours of a completed form. Forms are faxed to 1-888-508-8200. A Patient Starter Kit of support materials is available on request.
The official page does not say who qualifies. Ask the program. · source
Good to know: Read on novocare.com on November 17, 2026. No income limit is published. NovoCare's JumpStart program for insurance delays is not available for Norditropin, and no bridge or free trial supply is described.
Access and eligibility
Approved for children with short stature from Noonan syndrome or Turner syndrome and for children with growth failure from Prader-Willi syndrome[1]. Norditropin is not used for growth once the growth plates have closed[1]. In Prader-Willi syndrome, it is not used in children who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing problems[1]. Other reasons it is not used include an active cancer, acute critical illness and active proliferative or severe non-proliferative diabetic eye disease[1]. The label also covers growth hormone deficiency in adults, but its uses for these 3 syndromes are in children[1].
Source: NovoCare
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
Noonan syndrome: a 2-year randomized study gave 21 children aged 3 to 14 either 0.033mg/kg or 0.066mg/kg a day, with 6 more children following the same plan, and treatment continued to adult height[1]. Growth in the first 2 years was 10.1cm and 7.6cm a year on the higher dose against 8.55cm and 6.7cm on the lower dose[1]. Compared with historical height records rather than an untreated group, children gained 1.5 standard deviations of height against the general population, about 9.9cm for boys and 9.1cm for girls at age 18[1].
Turner syndrome: in a Dutch study of 68 girls, 46 reached final height after a mean of 8.4 years, averaging 161cm, and 70% reached a height in the normal range[1]. Girls whose dose was raised after the first year did better than girls kept on 0.045mg/kg a day: 80% and 83% reached normal height against 53%[1]. Girls who had not started puberty on their own also got estrogen in that study[1].
A second Dutch study of 19 older girls, mean age 13.6, reported a mean final height of 155cm in the 17 who reached it[1]. Prader-Willi syndrome: the label rests on 2 studies of another somatropin product that compared it with no treatment for the first year, in which treated children grew 11.6cm and 10.7cm that year against 5.0cm and 4.3cm untreated[1]. The label reports no trial comparing Norditropin directly with another growth hormone product[1].
Development history
Novo Nordisk says Norditropin was first approved by the FDA in 1995[6]. The current application, 21-148, was first approved on June 20, 2000, and Drugs@FDA notes that it was deemed a biologics license application (BLA) on March 23, 2020[2]. The FDA approved short stature in children with Noonan syndrome on May 31, 2007 and short stature in children with Turner syndrome on September 20, 2007[3][4].
Novo Nordisk filed for idiopathic short stature and Prader-Willi syndrome on March 29, 2012, the FDA sent an action letter on April 25, 2016, and both uses were approved on February 23, 2018 after Novo Nordisk's response in August 2017[5]. The label updated in July 2025 lists a change to its slipped capital femoral epiphysis warning[1].
Explore Noonan Syndrome and Turner Syndrome and Prader-Willi Syndrome trials
Other Noonan Syndrome & Turner Syndrome treatments
Common questions about Somatropin
▸What is Somatropin (Norditropin)?
Norditropin is a growth hormone shot given under the skin with a prefilled FlexPro pen, 6 or 7 days a week[1]. Its label covers children with short stature from Noonan syndrome or Turner syndrome and children with growth failure from Prader-Willi syndrome, along with growth hormone deficiency in children and adults, children born small for gestational age who have not caught up by age 2 to 4, and idiopathic short stature[1]. The FDA added Noonan syndrome on May 31, 2007, Turner syndrome on September 20, 2007 and Prader-Willi syndrome on February 23, 2018[3][4][5]. The label has no boxed warning, and Norditropin is not used in children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing problems, because sudden deaths have been reported[1].
▸How does Somatropin work?
Somatropin is human growth hormone made with recombinant DNA technology in E. coli bacteria, and its 191 amino acids match the growth hormone made by the pituitary gland[1]. Somatropin attaches to growth hormone receptors on cells, which switches on proteins including IGF-1, a hormone that carries much of growth hormone's effect[1]. In children, the label says somatropin speeds growth by acting on the growth plates (epiphyses) at the ends of the long bones, which is why it is stopped for growth once those plates have closed[1]. Somatropin also changes metabolism: it increases protein building and fat breakdown, raises sugar output from the liver and can lower insulin sensitivity[1]. The label's uses in these 3 syndromes are about height, meaning short stature in Noonan syndrome and Turner syndrome and growth failure in Prader-Willi syndrome[1].
▸What are the side effects of Somatropin?
The current Norditropin label has no boxed warning[1]. Its warnings cover sudden death in children with Prader-Willi syndrome who are severely obese or have airway or breathing problems; higher death rates in critically ill adults; tumor growth or a second tumor; high blood sugar and diabetes; raised pressure around the brain; serious allergic reactions; fluid retention; low cortisol; an underactive thyroid; slipped capital femoral epiphysis, a hip problem at the growth plate; worsening of existing scoliosis; pancreatitis; and fat loss where shots are repeated[1]. The label lists upper respiratory infection, fever, sore throat, headache, ear infection, swelling, joint pain, tingling, muscle pain, flu-like illness and impaired glucose tolerance as common side effects across children and adults[1]. In the Noonan syndrome study, the most frequent side effects were upper respiratory infection, stomach flu, ear infection and influenza, heart-related problems were the second most reported group, and scoliosis was reported in 1 child on the lower dose and 4 on the higher dose[1]. In the Turner syndrome studies, the most frequent were flu-like illness, middle and outer ear infections, upper respiratory infection, stomach flu, eczema and raised fasting blood sugar; 3 girls on high doses had excess growth of the hands or feet, and 2 girls on 0.045mg/kg a day had serious worsening of existing scoliosis[1]. In 2 Prader-Willi syndrome studies of another somatropin product, reported side effects were swelling, aggressiveness, joint pain, raised pressure around the brain, hair loss, headache and muscle pain[1]. In adults with growth hormone deficiency, a 6-month placebo-controlled trial found swelling of the legs and arms in 42% on Norditropin against 8% on placebo, joint pain in 19% against 15% and muscle pain in 15% against 8%[1]. Blood levels of phosphorus, alkaline phosphatase, parathyroid hormone and IGF-1 may rise during treatment[1].
▸How is Somatropin taken?
Norditropin is injected under the skin of the back of the upper arm, the abdomen, the buttock or the thigh, rotating sites each time[1]. For children, the doctor works out a weekly dose by body weight and splits it into equal shots given 6 or 7 days a week[1]. The label doses are up to 0.46mg/kg a week (up to 0.066mg/kg a day) for Noonan syndrome, up to 0.47mg/kg a week (up to 0.067mg/kg a day) for Turner syndrome and 0.24mg/kg a week (0.034mg/kg a day) for Prader-Willi syndrome, adjusted to how each child grows[1]. Treatment for growth stops once the growth plates have closed[1]. Norditropin comes as a clear, colorless liquid in single-patient FlexPro prefilled pens of 5mg/1.5mL (orange), 10mg/1.5mL (blue), 15mg/1.5mL (green) and 30mg/3mL (purple)[1]. The 5mg, 10mg and 15mg pens work with the FlexPro PenMate, an accessory device dispensed separately, and the 30mg pen does not[1]. A pen is never shared, even with a new needle[1]. Unused pens are kept in the refrigerator and never frozen; after the first shot, a pen lasts 4 weeks in the refrigerator or 3 weeks at room temperature up to 77°F[1]. The label says people on steroid replacement may need a higher steroid dose, people on oral estrogen may need more Norditropin, and diabetes medicines may need adjusting[1].
▸Is Somatropin FDA approved?
Yes. The FDA approved Norditropin for short stature in children with Noonan syndrome on May 31, 2007, for short stature in children with Turner syndrome on September 20, 2007 and for growth failure in children with Prader-Willi syndrome on February 23, 2018.
Other uses: growth hormone deficiency in children and adults, children born small for gestational age who have not caught up by age 2 to 4, and idiopathic short stature.
Prader-Willi limit: not used in children who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing problems.
Growth plates: not used for growth once the growth plates have closed.
Source: Norditropin prescribing information and Drugs@FDA BLA 021148
▸What is the Norditropin dose for Noonan syndrome, Turner syndrome and Prader-Willi syndrome?
The label sets a weekly dose by body weight, split into equal shots given 6 or 7 days a week[1].
Noonan syndrome: up to 0.46mg/kg a week, which is up to 0.066mg/kg a day.
Turner syndrome: up to 0.47mg/kg a week, which is up to 0.067mg/kg a day.
Prader-Willi syndrome: 0.24mg/kg a week, which is 0.034mg/kg a day.
Adjusting: the doctor sets each child's dose by how the child grows.
▸Is growth hormone safe for children with Prader-Willi syndrome?
The Norditropin label carries a warning about sudden deaths reported after starting somatropin in children with Prader-Willi syndrome who had certain risk factors[1].
Risk factors: severe obesity, a history of upper airway obstruction or sleep apnea, or an unidentified breathing infection.
Boys: boys with these risk factors may be at greater risk than girls.
Before starting: children are checked for airway blockage and sleep apnea.
During treatment: the label calls for weight control and early treatment of breathing infections, and treatment is paused for new or louder snoring or new sleep apnea.
▸How much taller did girls with Turner syndrome grow on Norditropin?
In a Dutch study of 68 girls, the 46 who reached final height averaged 161cm, and 70% reached a height in the normal range[1].
Dose: 80% and 83% reached normal height when the dose was raised after year 1, against 53% on 0.045mg/kg a day throughout.
Gain: about 9.1cm and 9.4cm against the general population on the raised doses, and 4.5cm on the steady dose.
Estrogen: girls without spontaneous puberty also got estrogen.
▸Is there help paying for Norditropin?
NovoCare offers a savings offer for commercially insured patients and a patient assistance program for people who qualify[13][14].
Savings offer: pay as little as $0 a year, up to an annual maximum of $1,500 in savings.
Not eligible: anyone with a government-funded prescription benefit, including people who also have a commercial plan.
Free drug: the patient assistance program may give Norditropin free to people without coverage and with limited means; no income limit is published.
Phone: 1-888-668-6444, 8AM to 8PM ET, Monday to Friday.
Source: NovoCare Norditropin page
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Novo Nordisk via DailyMed · 2025-07-07. NORDITROPIN- somatropin injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14
- U.S. Food and Drug Administration · 2000-06-20. NORDITROPIN approval history, BLA 021148. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021148
- U.S. Food and Drug Administration · 2007-05-31. NDA 21-148/S-016 approval letter (Norditropin, Noonan syndrome). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021148s016ltr.pdf
- U.S. Food and Drug Administration · 2007-09-20. NDA 21-148/S-017 approval letter (Norditropin, Turner syndrome). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021148s017ltr.pdf
- U.S. Food and Drug Administration · 2018-02-23. NDA 021148/S-037, S-038 supplement approval (Norditropin, idiopathic short stature and Prader-Willi syndrome). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/021148Orig1s037s038ltr.pdf
- Novo Nordisk (NovoMedLink). What is Norditropin®? | Norditropin® (somatropin) Injection 10 mg. https://www.novomedlink.com/growth-related-disorders/products/treatments/norditropin/about.html
- Novo Nordisk via DailyMed · 2026-02-25. SOGROYA- somapacitan-beco injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eadd03b4-adc3-4b88-8a24-9d205c5b85aa
- Pfizer Laboratories Div Pfizer Inc via DailyMed · 2026-08-04. GENOTROPIN- somatropin kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765
- Eli Lilly and Company via DailyMed · 2026-08-20. HUMATROPE- somatropin kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409
- Sandoz Inc via DailyMed · 2025-07-10. OMNITROPE- somatropin injection, solution / OMNITROPE- somatropin kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5
- U.S. National Library of Medicine, DailyMed · 2025-03. VYKAT XR (diazoxide choline) extended-release tablets: prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e745e85-9512-e360-e063-6394a90aebf1
- Ferring Pharmaceuticals Inc. via DailyMed · 2026-04-20. ZOMACTON- somatropin kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886
- Novo Nordisk. Insurance Coverage and Savings Resources for Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg Pens | NovoCare®. https://www.novocare.com/growth-related-disorders/products/norditropin.html
- Novo Nordisk. Request your Norditropin® Savings Offer. https://www.novocare.com/growth-related-disorders/products/norditropin/savings-offer.html
- Novo Nordisk. Savings and Support for Growth-related Disorders | NovoCare®. https://www.novocare.com/hcp/growth-related-disorders/savings-and-support.html